Eterna Therapeutics INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Ernexa Therapeutics Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for July 1, 2026, to elect directors, ratify auditors, and approve an equity incentive plan.
NASDAQ
Ernexa Therapeutics aims to regain Nasdaq compliance and enhance stock appeal through a reverse stock split, while also seeking approval for increased authorized shares and a securities purchase agreement.
NASDAQ
DEF 14A: Eterna Therapeutics Seeks Stockholder Approval for Key Proposals at Upcoming Annual Meeting
Eterna Therapeutics is asking stockholders to vote on the election of directors, ratification of auditors, and a stock issuance proposal at its annual meeting on October 29, 2024.